Clinical Trials Logo

Clinical Trial Summary

Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)


Clinical Trial Description

an open-label, single-center, phase 2, single-arm trial ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03943602
Study type Interventional
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Daniele Raggi, MD
Phone +390223902402
Email daniele.raggi@istitutotumori.mi.it
Status Recruiting
Phase Phase 2
Start date August 1, 2019
Completion date September 1, 2022

See also
  Status Clinical Trial Phase
Terminated NCT02837042 - Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Phase 2
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Recruiting NCT03774901 - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Phase 2
Not yet recruiting NCT06353906 - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Phase 2
Active, not recruiting NCT02496208 - Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Phase 1
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Completed NCT06068998 - Molecular Characterization of Penile Cancers in Developing Countries